晚期大肠癌ERCC5基因启动子-763A>G多态性与铂类药物疗效相关性的研究  

Relationship between ERCC5-763A>G polymorphism and clinical outcome of patients with advanced colorectal cancer treated with platinum-based chemotherapy

作　　者：陈建芳[1] 李建军[1] 蒋金妍[1] 邹岚[1] 裴莉[1] 潘凤[1] 梁后杰[1] 

机构地区：[1]第三军医大学西南医院肿瘤中心,重庆400038

出　　处：《中华肿瘤防治杂志》2010年第24期2010-2014,共5页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨ERCC5基因启动子区单核苷酸多态性与中国汉族晚期大肠癌奥沙利铂疗效的相关性。方法:收集以奥沙利铂为主化疗的105例晚期大肠癌患者化疗开始前静脉血,提取基因组DNA,应用PCR-LDR方法检测ERCC5基因3个SNP位点-1415C>T(rs2094258)-7、63A>G(rs2016073)及-413C>T(rs943245)多态性,分析不同基因型与疾病控制率、无进展生存期(PFS)的相关性。结果:携带ERCC5-763GG-、763AG和-763AA基因型的患者化疗疾病控制率分别为86.7%、69.2%和52.6%,其中携带-763GG基因型的患者疾病控制率显著高于携带-763AA基因型的患者,P=0.028。携带-763AA基因型的患者中位PFS(36/95例,6个月)低于携带-763AG基因型(48/95例,8个月)及携带-763GG基因型(11/95例,10个月)的患者,差异有统计学意义,χ2=9.205,P=0.002。-1415C>T多态性与化疗疾病控制率和PFS之间均无显著相关性。-413C>T位点未发现遗传多态。结论:ERCC5启动子区-763A>G单核苷酸多态性与晚期大肠癌奥沙利铂临床疗效相关。OBJECTIVE：To study the relationship between single nucleotide polymorphisms （SNP） in the promoter of ERCC5 （excision repair cross complementation group 5）gene and clinical outcome of Chinese patients with advanced colorectal cancer treated with oxaliplatin-based chemotherapy. METHODS： DNA was extracted from peripheral blood cells before oxaliplatin-based chemotherapy in 105 advanced colorectal cancer patients. Three polymorphisms in the ERCC5 genepromoter, 1415C〉T （rs2094258）, -763A〉G （rs2016078） and -413C〉T （rs943245） were detected by PCR-LDR （polymerase chain reaction-ligation detection reaction）. A statistical analysis was conducted to investigate the association between polymorphism and clinical outcome. RESULTS： The disease control rates were 86. 7〉 for patients with-763GG genotype, 69.2〉 for-763AG genotype respectively, and 52.6〉 for -763AA genotype. The disease control rate among patients with -763GG genotype was significantly higher than that among those carrying-763AA genotype （P= 0. 028）. The median progression free survival （PFS） among patients with the-763AA genotype （36/95 cases, 6 months） was significantly lower than that among ones with other genotypes （48/95 case, 8 months for -763AG genotype and 11/95 cases, 10 months for -763GG genotype, Х^2 = 9. 205, P = 0. 002）. No significant association or trend was found between -1415C 〉T polymorphism and disease control rate or PFS. Only CC genotype was observed at site -413C〉T and no genetic variation was observed. CONCLUSION： ERCC5-763A〉 G polymorphism may be associated with the clinical outcome of oxaliplatin based chemotherapy in Chinese patients with advanced colorectal cancer.

关 键 词：大肠肿瘤/药物疗法 切除修复交叉互补基因5 多态性 

分 类 号：R735.34[医药卫生—肿瘤]